You are here

P&T News

March 21

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth

March 19

Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness

March 14

National Statistics Report Factors In Race, Ethnicity for the First Time
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Synergistic Effects Seen When Combined With Cisplatin in Mice

March 12

Purportedly Sterile Products Made in Unsanitary Conditions, Judge Says
Small-Molecule Drug Blocks Oxidative Stress Signals
For Locally Advanced or Metastatic Triple-Negative Type Only
41,000+ Medical Device Reports of Deaths, Serious Injuries, and Malfunctions in 7 Years

March 5

MP-101 Has Potential to Drastically Alter Disease Progression
ACE-083 May Improve Strength in Target Muscles, Enhance Quality of Life
Bone-Marrow Transplant Succeeded, But Still Considered Risky
Safety Risks for Patients Undergoing Mastectomies and Cancer Surgeries

February 28

Subcutaneous Extended-Release Injectable With Risperidone Now Available in the U.S.
Treatment Options Are Limited After Failure of First- and Second-line Therapies
Possible Danger With Stopping and Starting Anti-Rejection Drugs
Minimally Invasive Procedure Uses Radio Waves to Thwart Pain

February 26

UCLA Scientists Develop Rapid Screening Method for Hundreds of Drugs
Researchers Seek Ways to Prevent Diabetes Onset in High-Risk Patients
Peak Immune Responses Occur as Early as Seven Days After Treatment
Addressing an Unmet Need in Patients With Burdensome Disease
FDA, CDC, and CMS Team Up To Improve Disaster Response Planning

February 21

Several Health Insurers Now Consider DBS Therapy for Epilepsy a Covered Indication